Casdin Capital’s Atara Biotherapeutics ATRA Stock Holding History

Casdin Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,000	Closed	-$660K	–	28
2015 Q4	$660K	Buy	+1,000	New	+$756K	0.58%	27

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital's ATRA Position: Q1 2016 in Review

Casdin Capital sold out of Atara Biotherapeutics (ATRA) in Q1 2016, closing a stake of 1,000 shares — an estimated $660K sold.

Casdin Capital first reported a position in ATRA in Q4 2015 and held it in 1 quarter. The position peaked at $660K in Q4 2015. 71 funds tracked by Wall St. Rank hold ATRA as of Q1 2016.

Casdin Capital reported no remaining Atara Biotherapeutics position as of Q1 2016 after selling out during the quarter.
Casdin Capital sold 1,000 Atara Biotherapeutics shares in Q1 2016, an estimated $660K.
Casdin Capital first reported a position in Atara Biotherapeutics in Q4 2015 and held it in 1 quarter.
Casdin Capital's Atara Biotherapeutics position peaked at $660K in Q4 2015.
71 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2016.

Based on Casdin Capital's 13F filing for Q1 2016, filed 9 May 2016.